Biocept Names David Karlander as Senior Vice President of Commercial Operations
August 03 2021 - 8:17AM
Business Wire
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, has appointed David
Karlander as Senior Vice President of Commercial Operations. With
more than 25 years of industry experience, Karlander will lead all
aspects of commercialization, including sales, marketing and
reimbursement, and will report to Biocept President and CEO Michael
Nall.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210803005060/en/
David Karlander, Senior Vice President of
Commercial Operations at Biocept. (Photo: Business Wire)
“Dave’s breadth of experience across diagnostic technologies and
commercial functions makes him an excellent fit for Biocept,” said
Nall. “As we advance our core oncology business, particularly with
the commercialization of our neuro-oncology assay CNSide™, Dave’s
expertise will help us to achieve our commercial goals and support
our strategic initiatives. We are pleased to welcome Dave to
Biocept.”
Karlander brings extensive healthcare and oncology industry
experience, successfully building and managing major brands in
diagnostics, devices and pharmaceuticals throughout all stages of
commercialization. He most recently served as Head of Clinical and
Translational Sales at Mission Bio, where he led the field-based
and inside sales organizations in a high-growth start-up
environment. He spent the previous decade in executive sales and
marketing positions at Exact Sciences and Novartis’ Genoptix
Medical Lab, leading successful campaigns to expand product
pipelines, reimbursement rates and sales volumes. Karlander earned
his MBA from Northwestern University’s Kellogg Graduate School of
Management and a Bachelor of Science from Miami University.
“I’m excited and proud to join the Biocept team and to support
our mission of improving cancer outcomes, while serving our
community with COVID-19 testing,” Karlander said. “I look forward
to contributing to Biocept’s continued expansion, especially with
the advancement of CNSide, which has the potential to improve the
lives of patients with metastatic cancer.”
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "will," "designed," "look
forward to" and "potential" or comparable terminology. To the
extent that statements in this release are not strictly historical,
including without limitation statements regarding the potential of
CNSide to diagnose cancer that has metastasized to the central
nervous system and improve the lives of patients with metastatic
cancer, Biocept’s growth, the achievement of commercial goals and
strategic initiatives, and the ability of Biocept’s molecular
diagnostic assays to provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risks and uncertainties,
including the risk that our products and services may not perform
as expected. These and other risks are described in greater detail
under the "Risk Factors" heading of our Quarterly Report on Form
10-Q for the quarter ended March 31, 2021. The effects of such
risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803005060/en/
Biocept Contacts Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com,
310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024